Renin-Angiotensin system blockade: Time for a reappraisal?

European Heart Journal

Volumn 35, Issue 26, 2014, Pages 1703-1705

  Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; PLACEBO; RENIN INHIBITOR; AMIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE;

BORDERLINE HYPERTENSION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFICACY; EDITORIAL; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; FEMALE; MALE;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CORONARY ARTERY DISEASE; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE;

EID: 84925884352     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu129     Document Type: Editorial

References (19)

1. Ruilope LM. Current challenges in the clinical management of hypertension. Nat Rev Cardiol 2012;9:267-275.
2. Brown MJ. Aliskiren. Circulation 2008;118:773-784.
3. Segura J, Cerezo C, Garcia-Donaire JA, Schmieder RE, Praga M, de la Sierra A, Ruilope LM. Validation of a therapeutic scheme for the treatment of resistant hypertension. J Am Soc Hypertens 2011;5:498-504.
4. Gheorghiade M, BöhmM, Greene SJ, FonarowGC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP, ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissionsamong patients hospitalized for heart failure: The ASTRONAUT randomized trial. JAMA 2013;309:1125-1135.
5. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA, ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-22213.
6. Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, Brunel P, Nicolaides M, Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE. Effect of aliskiren on progression of coronary disease in patients with prehypertension: The AQUARIUS randomized clinical trial. JAMA 2013;310:1135-1144.
7. Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, Desai A, Gimpelewicz C, Kandra A, Reimund B, Rattunde H, Armbrecht J, ATMOSPHERE Investigators. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: Rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011;13:107-114.
8. Teo KK, Pfeffer M,Mancia G,O'Donnell M, Dagenais G, Diaz R, Dans A, Liu L, Bosch J, Joseph P, Copland I, Jung H, Pogue J, Yusuf S; on behalf of the Aliskiren Prevention of Later Life Outcomes trial Investigators. Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: The APOLLOtrial. Eur Heart J 2014;35:1743-1751.
9. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, Van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. Blood 2009;18:308-347.
10. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: A meta-analysis. JAMA 2011;305:913-922.
11. Sorbets E, Labreuche J, Tabassome S, Delorme L, Danchin N, Amarenco P, Goto S, Meune C, Eagle KA, Bhatt DL, Steg PG. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. Eur Heart J 2014;35:1760-1768.
12. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, CannonCP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL,REACHRegistry Investigators. b-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012;308:1340-1349.
13. Cerezo C,RuilopeLM, Segura J,Garcia-Donaire JA,de laCruz JJ,Banegas JR,Waeber B, Rabelink TJ, Messerli FH. Microalbuminuria breakthrough under chronic renin-angiotensin- aldosterone system suppression. J Hypertens 2012;30:204-209.
14. Blood Pressure Lowering Treatment Trialists' Collaborations, Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, Cass A, Baigent C, Chalmers J, Li N, Woodward M, MacMahon S Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: Meta-analysis of randomised controlled trial. BMJ 2013;347:f5680.
15. Ruilope LM, Bakris GL. Renal function and target organ damage in hypertension. Eur Heart J 2011;32:1599-1604.
16. Ruilope LM. Long-Term adherence to therapy: The clue to prevent hypertension consequences. Eur Heart J 2013;34:2931-2932.
17. Lakkis J, Lu WX,Weir MR.RAAS escape: A real clinical entity thatmaybe important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003;5: 408-417.
18. Lang CC, Struthers AD. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol 2013;10:125-134.
19. McMurray JJ, Packer M, Desai AS, Leftkowitz MP, Rizkala AR, Rouleau J, Solomon SD, Swedberg K, Zile MR. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-Converting enzyme inhibition in patients with chronic systolic heart failure: Rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADGM-HF). Eur J Heart Fail 2013;15: 1062-1073.